WARNING: AGRANULOCYTOSIS; ORTHOSTATIC HYPOTENSION, BRADYCARDIA, AND SYNCOPE; SEIZURE; MYOCARDITIS AND CARDIOMYOPATHY; INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
CLOZARIL treatment has caused agranulocytosis, defined as an absolute neutrophil count (ANC) less than 500/mm. Agranulocytosis can lead to serious infection and death. Prior to initiating treatment with CLOZARIL, obtain a baseline white blood cell (WBC) count and ANC. The ANC must be greater than or equal to 2000/mm and the WBC must be greater than or equal to 3500/mm for a patient to begin treatment with CLOZARIL. During treatment, patients must have regular monitoring of ANC and WBC. Discontinue CLOZARIL and do not rechallenge if the ANC is less than 1000/mm or the WBC is less than 2000/mm. Advise patients to immediately report symptoms consistent with agranulocytosis or infection (e.g., fever, weakness, lethargy, or sore throat).
[see Dosage and Administration and Warnings and Precautions]
Because of the risk of agranulocytosis, CLOZARIL is available only through a restricted program called the CLOZARIL National Registry. Under the CLOZARIL National Registry, prescribers, patients, and pharmacies must enroll in the program.
[see Warnings and Precautions]
Orthostatic Hypotension, Bradycardia, Syncope
Orthostatic hypotension, bradycardia, syncope, and cardiac arrest have occurred with CLOZARIL treatment. The risk is highest during the initial titration period, particularly with rapid dose escalation. These reactions can occur with the first dose, with doses as low as 12.5 mg per day. Initiate treatment at 12.5 mg once or twice daily; titrate slowly; and use divided dosages. Use CLOZARIL cautiously in patients with cardiovascular or cerebrovascular disease or conditions predisposing to hypotension (e.g., dehydration, use of antihypertensive medications).
[see Dosage and Administration (2.2, and 2.5) and Warnings and Precautions]
Seizures have occurred with CLOZARIL treatment. The risk is dose-related. Initiate treatment at 12.5 mg, titrate gradually, and use divided dosing. Use caution when administering CLOZARIL to patients with a history of seizures or other predisposing risk factors for seizure (CNS pathology, medications that lower the seizure threshold, alcohol abuse). Caution patients about engaging in any activity where sudden loss of consciousness could cause serious risk to themselves or others.
[see Dosage and Administration Warnings and Precautions]
Myocarditis and Cardiomyopathy
Fatal myocarditis and cardiomyopathy have occurred with CLOZARIL treatment. Discontinue CLOZARIL and obtain a cardiac evaluation upon suspicion of these reactions. Generally, patients with CLOZARIL-related myocarditis or cardiomyopathy should not be rechallenged with CLOZARIL. Consider the possibility of myocarditis or cardiomyopathy if chest pain, tachycardia, palpitations, dyspnea, fever, flu-like symptoms, hypotension, or ECG changes occur.
[see Warnings and Precautions]
Increased Mortality in Elderly Patients with Dementia-Related Psychosis
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. CLOZARIL is not approved for use in patients with dementia-related psychosis.
[see Warnings and Precautions]
CLOZARIL (clozapine), an atypical antipsychotic drug, is a tricyclic dibenzodiazepine derivative, 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo [b,e] [1,4] diazepine.
Treatment Resistant Schizophrenia
CLOZARIL is indicated for the treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment. Because of the significant risk of agranulocytosis and seizure associated with its use, CLOZARIL should be used only in patients who have failed to respond adequately to standard antipsychotic treatment.
[see Warnings and Precautions (5.1, 5.4)]
The effectiveness of CLOZARIL in treatment-resistant schizophrenia was demonstrated in a 6-week, randomized, double-blind, active-controlled study comparing CLOZARIL and chlorpromazine in patients who had failed other antipsychotics.
[see Clinical Studies]
Reduction in the Risk of Recurrent Suicidal Behavior in Schizophrenia or Schizoaffective Disorder
CLOZARIL is indicated for reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder who are judged to be at chronic risk for re-experiencing suicidal behavior, based on history and recent clinical state. Suicidal behavior refers to actions by a patient that put him/herself at risk for death.
The effectiveness of CLOZARIL in reducing the risk of recurrent suicidal behavior was demonstrated over a 2-year treatment period in the InterSePT trial.
[see Clinical Studies]
Media Articles Related to Clozaril (Clozapine)
Menstrual Psychosis: A Forgotten Disorder?
Source: Medscape Family Medicine Headlines [2015.09.21]
This cause of recurrent psychosis in women is reclaiming our attention.
Can speech patterns predict psychosis in young adults?
Source: Schizophrenia News From Medical News Today [2015.08.27]
Could computers analyzing speech find a place in the clinic as a means of picking out young people at risk of psychosis? A proof-of-principle study shows they could.
Omega-3s May Protect Against Psychosis
Source: MedicineNet Bipolar Disorder Specialty [2015.08.12]
Title: Omega-3s May Protect Against Psychosis
Category: Health News
Created: 8/12/2015 12:00:00 AM
Last Editorial Review: 8/12/2015 12:00:00 AM
Source: MedicineNet Panic Disorder Specialty [2015.05.14]
Title: ICU Psychosis
Category: Diseases and Conditions
Created: 12/10/1998 12:00:00 AM
Last Editorial Review: 5/14/2015 12:00:00 AM
Rise in numbers of teenagers given antipsychotics
Source: Bipolar News From Medical News Today [2015.07.02]
Teenagers between 13 and 18 are being treated more with antipsychotics, and mostly for conditions that do not involve psychosis, study suggests.
Published Studies Related to Clozaril (Clozapine)
Non-glutamatergic clozapine augmentation strategies: a review and meta-analysis. 
Persistent negative symptoms and cognitive impairment are major clinical problems
in the treatment of schizophrenia. There is no convincing evidence regarding the
efficacy of augmentation of clozapine with a second antipsychotic, ethyl
eicosapentaenoic acid (E-EPA), an antidepressant, a mood stabilizer or extract of
Ginkgo biloba in clozapine-resistant schizophrenia.
Efficacy of pimozide augmentation for clozapine partial responders with
INTRODUCTION: A substantial number of patients with treatment-resistant
schizophrenia respond only partially to clozapine... DISCUSSION: In this well controlled clinical trial of patients with
treatment-resistant schizophrenia currently receiving clozapine, pimozide
augmentation was not an effective strategy to maximize the benefit for better
control of positive and negative symptoms or improving neurocognitive function.
Choice of randomization to clozapine versus other second generation
antipsychotics in the CATIE schizophrenia trial. 
There is evidence to suggest that clozapine is underutilized in
treatment-refractory schizophrenia. Data from the Clinical Antipsychotic Trials
of Intervention Effectiveness (CATIE), a multi-phase, randomized comparative
effectiveness trial for schizophrenia, were used to identify factors associated
with choosing randomization to clozapine...
Effects of sertindole on cognition in clozapine-treated schizophrenia patients. 
CONCLUSION: The clozapine-treated patients displayed marked cognitive deficits at
Augmentation of clozapine with a second antipsychotic - a meta-analysis. 
CONCLUSION: Augmentation with a second antipsychotic is modestly beneficial in
Clinical Trials Related to Clozaril (Clozapine)
A Study to Compare the Pharmacokinetics Profile of DWCZP Tablet 100mg and ClozarilŪ Tablet 100mg [Completed]
Equivalence of Generic Clozapine to Orally Dissolving Clozapine in Schizophrenia or Schizoaffective Disorder [Completed]
Study of the Effect of Dosing on Clozapine Levels [Not yet recruiting]
The objectives of this 15-day study are:
1. To compare steady-state trough plasma concentrations of clozapine and its metabolite
norclozapine when given once daily and twice daily (at the same total daily dose)
2. To determine if frequency of clozapine administration has an effect on:
1. Symptoms of schizophrenia
2. Adverse effects of clozapine
3. Fasting blood glucose, lipids, creatinine, and urea
4. Weight and waist circumference
Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual [Completed]
Many individuals with schizophrenia also suffer from marijuana addiction. Clozapine, an
atypical antipsychotic medication, may prove useful at preventing drug relapse in
schizophrenic individuals who are seeking treatment for marijuana addiction. The purpose of
this study is to compare the effectiveness of clozapine, vs. treatment-as-usual with other
oral antipsychotics at reducing marijuana use in schizophrenic individuals.
Clozapine Versus Amisulpride in Treatment-resistant Schizophrenia Patients [Recruiting]
Background: schizophrenia is a debilitating mental disorder affecting about 1% of the
general population. About 30% of patients will not react to current drug treatment and
defined as treatment-resistant schizophrenia patients (TRSP). The best studied therapeutic
option for this population is clozapine therapy. Clozapine was shown to be effective than
any other antipsychotic drug in TRSP. Moreover, augmentation of clozapine was not
demonstrated to be more effective than clozapine monotherapy. Albeit Clozapine superiority
in TRSP, its use may be involved with many adverse effects, some of them are
life-threatening, and need for routine blood tests. Amisulpride is an atypical antipsychotic
drug with a different mechanism of action than clozapine, with less adverse effects. No
study compared directly amisulpride and clozapine in TRSP.
Study objective: to compare, for the first time, the broad clinical effectiveness of
clozapine and amisulpride and their combination in TRSP.
Study Design: a clinical, prospective, naturalistic, randomized, comparative study
simulating a real-world approach of clinical decision making.
Methods: a total of 140 TRSP will be recruited from a large regional mental health center.
Participants will be randomized into two treatment groups (70 in each group): clozapine
monotherapy and amisulpride monotherapy. Assessment will be done following 10 and 20 weeks
of treatment. In case of treatment failure (insufficient clinical response or severe
adverse effect) participants will be offered either to switch to clozapine treatment (for
failed amisulpride treatment) or to augment clozapine with amisulpride (for failed clozapine
monotherapy patients). Thereafter, participants will be followed-up for a year. Assessment
will be made using clinician rated scales and self-completed questionnaires, rating the
broad phenomenology of schizophrenia (psychosis, mood, anxiety, obsessive-compulsive,
cognitive and quality of life) and drug-related adverse effects (objective and subjective).
Analysis: comparison of the effectiveness of the three treatment groups: amisulpride,
clozapine and their combination, in the various dimensions of TRSP.
Reports of Suspected Clozaril (Clozapine) Side Effects
White Blood Cell Count Increased (651),
White Blood Cell Count Decreased (523),
Neutrophil Count Increased (513),
Neutrophil Count Decreased (407),
Platelet Count Decreased (398),
Haemoglobin Decreased (310),
Pyrexia (235), more >>
Page last updated: 2015-09-21